- TRADE NAME: Synagis (Medimmune)
- INDICATIONS: Prophylaxis of serious lower respiratory tract disease caused by respiratory syncytial virus in pediatric patients
- CLASS: Immunomodulator, Monoclonal antibody
- HALF-LIFE: 18 days
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
